C-erbB-2、p53、ER和PR受体在乳腺癌组织中的表达及意义  

The expression of C-erbB-2,p53,ER and PR in breast carcinoma and their clinical significance

作　　者：吴一萍[1] 曹晓智[1] 

机构地区：[1]皖南医学院附属二院肿瘤科,安徽芜湖241000

出　　处：《中国肿瘤临床与康复》2009年第2期105-107,共3页Chinese Journal of Clinical Oncology and Rehabilitation

摘　　要：目的分析研究C-erbB-2、p53、ER、PR在乳腺癌中的表达与分期、转移关系及临床意义。方法用免疫组化法测定83例原发性乳腺癌C-erbB-2、p53、ER、PR的表达情况,进行对照比较。结果C-erbB-2、p53、ER、PR阳性表达者分别为30例(36.1%)、31例(37.3%)、45例(54.2%)、53例(63.9%)。C-erbB-2的表达与p53呈正相关(P<0.05),与ER、PR呈负相关(P<0.05)。C-erbB-2和p53的表达率随着临床分期增加和淋巴结转移而增加,差异有显著性(P<0.05)。ER、PR阳性表达率随着临床分期的递增和淋巴结转移的减少而降低,差异无显著性(P>0.05)。ER、PR阳性表达率与C-erbB-2、p53表达呈负相关,差异无显著性(P>0.05)。结论C-erbB-2、p53是判断乳腺癌预后的有效指标,ER、PR与临床分期及腋窝淋巴结转移有一定关系,联合检测C-erbB-2、p53、ER、PR可指导临床综合治疗。Objective To study the expression of C-erbB-2, p53,ER and PR in breast carcinoma and their relationship with stages, metastasis and clinical significance. Methods The expression of C-erbB- 2, p53, ER and PR was examined with immunohistoehemical S-P technique in 83 cases of breast carcinoma.Results In 83 cases of breast carcinoma, the positive rate of C-erbB-2 was 36. 1% （30/80）, p53 was 37. 3% （31/83） ,ER was 54. 2% （45/83） ans PR was 63.9% （53/83）. The expression of C-erbB-2 was positively correlated with p53 （ P 〈0. 05 ） , and negatively correlated with ER and PR （ P 〈 0. 05 ）. The expression rates of C-erbB-2 and p53 increased with increasing clinical stages and lymphatic metastasis, and there was significant difference （ P 〈 0. 05 ）. The expression rates of ER and PR decreased with increasing clinical stages and decreasing lymphatic metastasis, with no significant difference （ P 〉 0. 05 ）. The expression rates of ER and PR had negative correlation with the expression of C-erbB-2 and p53 and there was no significant difference（P 〉0. 05）. Conclusions C-erbB-2 and p53 are useful prognostic factors in patients with breast carcinoma. The expression of ER and PR was associated with the clinical stage and lymphaticmetastasis of breast carcinoma. The combined detection of C-erbB-2, p53, ER and PR has important significance for clinical therapy.

关 键 词：乳腺肿瘤 免疫组织化学 C—erbB-2 P53 ER PR 

分 类 号：R737.9[医药卫生—肿瘤] R730.45[医药卫生—临床医学]